Multifactorial aspects of the treatment of the type II diabetic patient

Metabolism: Clinical and Experimental

Volumn 46, Issue SUPPL.1, 1997, Pages 1-4

  Colwell, John A ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; STREPTOKINASE; SULFONYLUREA DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA INJURY; THROMBOSIS;

ARTERIOSCLEROSIS; ASPIRIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 0031429537     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90308-5     Document Type: Article

References (26)

1. Stamler J, Vaccaro O, Neaton JD, et al: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. Kuusisto J, Mykkanen L, Pyorala K, et al: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
3. Andersson DKG, Svardsudd: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
4. Uusitupa MIJ, Niskanen LK, Siitonen O, et al: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184, 1993
5. Donahue RP, Abbott RD, Reed DM, et al: Post-challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36:689-692, 1987
6. McGill HC, McMahan A, Malcolm GT, et al: Arterioscler Thromb Vasc Biol 15:431-440, 1995
7. Colwell JA, Lyons TJ, Klein RL, et al: New concepts about the pathogenesis of atherosclerosis and thrombosis in diabetes mellitus, in Levin ME, O'Neal LW, Bowker JH (eds): The Diabetic Foot. St Louis, MO, Mosby, 1992, pp 79-114
8. Yamasaki Y, Kawamori R, Matzushima H, et al: Asymptomatic hyperglycemia is associated with increased intimai plus medial thickness of the carotid artery. Diabetologia 38:585-591, 1995
9. Knatterud GL, Klimt CR, Levin ME, et al: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 240:37-42, 1978
10. The United Kingdom Prospective Diabetes Study. XVII. A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Int Med 124:136-145, 1996
11. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
12. Malmberg K, Ryden L, Efendic S, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (the DIGAMI Study): Effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995
13. Abraira C, Colwell JA, Nuttal FQ, et al: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM): Results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
14. Colwell JA, Jokl R: Vascular thrombosis in diabetes, in Porte D, Sherwin R, Rifkin H (eds): Diabetes Mellitus: Theory and Practice (ed 5) Norwalk, CT, Appleton & Lange, 1996, pp 207-216
15. Kwaan HC, Colwell, JA, Cruz S, et al: Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 20:236-44, 1972
16. Sagel J, Colwell JA, Crook L, et al: Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82:733-738, 1975
17. Colwell JA, Sagel J, Crook L, et al: Correlation of platelet aggregation, "plasma factor" activity, and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism 26:279-285, 1977
18. Colwell JA, Lopes-Virella ML, Halushka PV: Pathogenesis of atherosclerosis in diabetes mellitus. 4:121-133, 1981
19. Colwell JA, Lopes-Virella MF: A review of the pathogenesis of large vessel disease in diabetes mellitus. Am J Med 85:113-118, 1988
20. Halushka PV, Rogers RC, Loadhold CB, et al: Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97:87-96, 1981
21. Steering Committee of the Physicians' Health Study Research Group: Final report of the aspirin component on the ongoing Physicians' Health Study. N Engl J Med 321:129-135, 1989
22. Early Treatment of Diabetic Retinopathy Study Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268:1292-1300, 1992
23. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:71-72, 81-106, 1994
24. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137-1141, 1991
25. Patrono C, Davi G: Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev 9: 1993
26. ISIS-2: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-360, 1988